Rule 14 Jul 2025 compliance, federal regulations, business impact, department of energy, nondiscrimination

⚖️Delay of Nondiscrimination Regulation Effective Date by DOE

Due to the receipt of significant adverse comments, the U.S. Department of Energy (DOE) is extending the effective date of the direct final rule "Rescinding Regulations Related to Nondiscrimination in Federally Assisted Programs or Activities (General Provisions)," published on May 16, 2025.

Learn More
Notice 14 Jul 2025 regulation, meeting notice, internal revenue service, taxpayer advocacy panel

📅Meeting Notice for Taxpayer Advocacy Panel on July 9, 2025

In the Federal Register that was originally published on June 11, 2025, the Designated Federal Officer signing this document is being changed to John A. Lipold. All other meeting details remain unchanged. This meeting will be held as a virtual video conference via the Microsoft Teams platform.

Learn More
Notice 14 Jul 2025 connectivity fees, nyse arca, securities regulation, third party systems, data feeds

📈NYSE Arca Connectivity Fee Schedule Rule Change

The NYSE Arca proposes amendments to its Connectivity Fee Schedule, affecting access to various third-party systems and data feeds. This includes the addition of new services, adjustments in fees, and guidelines on redistribution fees. The changes aim to enhance user options while maintaining competitive pricing for connectivity services, responding to market demands.

Learn More
Notice 14 Jul 2025 public meeting, regulation, noaa, minnesota, business engagement, coastal management

🌊NOAA to Evaluate Minnesota's Lake Superior Coastal Program

The National Oceanic and Atmospheric Administration's (NOAA) Office for Coastal Management will hold a virtual public meeting to solicit input on the performance evaluation of Minnesota's Lake Superior Coastal Program. NOAA also invites the public to submit written comments.

Learn More
Notice 14 Jul 2025 business compliance, pharmaceuticals, fda, regulatory review, patent extension

💊FDA Notice on Regulatory Review Period for ABRYSVO Patent Extension

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ABRYSVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

Learn More
Notice 14 Jul 2025 regulatory compliance, business implications, sunshine act meetings, federal mining safety, rockwell mining

⚖️Sunshine Act Meeting by Federal Mine Safety Review Commission

The Federal Mine Safety and Health Review Commission will hold a Sunshine Act meeting to consider a significant legal case concerning alleged violations of mine safety regulations by Rockwell Mining, LLC. The session will discuss past decisions and involve public accessibility options for attendees.

Learn More
Notice 14 Jul 2025 health, public health, data collection, cdc, surveillance

🏥CDC Notice on Proposed Data Collection for Public Comment

The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Emerging Infections Program (EIP). The EIP is a population-based surveillance program that collects data via active, laboratory case findings and is used for detecting, identifying, and monitoring emerging pathogens.

Learn More
Notice 14 Jul 2025 compliance, healthcare, regulations, dea, florida, pharmacy

💊Revocation of DEA Registration for JYA LLC - Major Implications

The Department of Justice has revoked the DEA registration of JYA LLC d/b/a Webb's Square Pharmacy due to serious violations, including dispensing controlled substances without legitimate prescriptions. The agency determined that these actions posed an imminent danger to public health, resulting in immediate sanctions and the denial of future registration applications. The ruling underscores the critical importance of compliance in pharmacy practice.

Learn More
Notice 14 Jul 2025 regulatory compliance, healthcare, pharmaceuticals, fda, patent extension

💊FDA Announces Regulatory Review Period for LAZCLUZE Patent Extension

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LAZCLUZE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

Learn More
Notice 14 Jul 2025 market data, compliance, securities, financial regulation, retail brokerage

📊Cboe EDGX Proposes Small Retail Broker Data Solutions Program

The Cboe EDGX Exchange proposes a new Small Retail Broker Hosted Solutions Program that aims to reduce fees and expand access to market data for retail brokers. By waiving distribution fees, the initiative seeks to foster broader service offerings and competitive pricing, enhancing opportunities for retail investors and smaller brokerage firms.

Learn More